Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04529902 · ClinicalTrials.gov registry record
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept
A clinical trial, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 63,013
- Enrollment target
NCT04529902: Completed study, sponsored by Brigham and Women's Hospital.
NCT04529902 is a clinical trial that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 63,013 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04529902 has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 63,013 participants
- Enrollment target
Study Summary
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Primary Outcome
Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.
Interventions
- DRUG Abatacept
- DRUG Tumor Necrosis Factor Inhibitors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63,013 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2021-08-31 |
What the finished NCT04529902 record still lists
NCT04529902 is an observational study that tracks outcomes without assigning an intervention. Its 63,013 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT04529902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04529902 about?
NCT04529902 is a clinical study titled "Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept". This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
What is the current status of trial NCT04529902?
This trial is currently completed. The enrollment target is 63,013 participants. The study started on 2020-08-17. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT04529902?
The interventions under investigation include: Abatacept (DRUG), Tumor Necrosis Factor Inhibitors (DRUG).
Who is sponsoring clinical trial NCT04529902?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06003192 · 63,000 participants · NA
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
- NCT05723614 · 61,770 participants · NA
TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI